Surgical procedure kit, ophthalmic, non-medicated, single-use Australia - English - Department of Health (Therapeutic Goods Administration)

surgical procedure kit, ophthalmic, non-medicated, single-use

medical concepts australia pty ltd - 45150 - surgical procedure kit, ophthalmic, non-medicated, single-use - a collection of variousopthalmic surgical instuments and the necessary accessories to perform an ophthalmic surgical procedure

Herbal World  Female (symbol) Rejuvenator Australia - English - Department of Health (Therapeutic Goods Administration)

herbal world female (symbol) rejuvenator

herbal world pty ltd - turnera diffusa, quantity: 37.5 microgram/ml (equivalent: turnera diffusa, qty 150 microgram/ml; equivalent: beta-arbutin, qty 1.05 microgram/ml); oenothera biennis, quantity: 25 microgram/ml (equivalent: oenothera biennis, qty 100 microgram/ml); dioscorea villosa, quantity: 625 microgram/ml (equivalent: dioscorea villosa, qty 2.5 mg/ml); malpighia glabra, quantity: 82.5 microgram/ml (equivalent: malpighia glabra, qty 825 microgram/ml; equivalent: ascorbic acid, qty 10 microgram/ml); matricaria chamomilla, quantity: 125 microgram/ml (equivalent: matricaria chamomilla, qty 500 microgram/ml) - oral liquid - excipient ingredients: potable water; sodium benzoate; carbon dioxide; sucrose; maltodextrin; citric acid; vanillin; linalool; delta-decalactone; neryl acetate; ethyl propionate; ethyl butyrate; citronellal; anethole; methyl benzoate; buchu leaf oil; dimethyl anthranilate; propylene glycol; phenethyl alcohol; mandarin oil; benzyl acetate; ethyl acetate; ethanol; orange oil; phenylacetaldehyde; cis-3-hexen-1-ol; geraniol; trans-2-hexenol; terpinen-4-ol; limonene; citral; maltol; menthone; ethyl caprate; petitgrain oil; isoamyl acetate; davana oil; rose oil; linalyl acetate; geranyl acetate; bergamot oil; benzaldehyde; l-menthyl acetate; orange flower oil; ethyl enantate; benzyl alcohol; alpha-phellandrene; isovaleric acid; geranyl butyrate; lemon oil terpeneless; cinnamon leaf oil; piperonal; gamma-decalactone; jasmine absolute; ginger oil; terpineol; hexyl acetate; acetic acid; 4-(para-hydroxyphenyl)-2-butanone; decanal; alpha-irone; alpha-terpineol; benzyl benzoate; caprylic aldehyde; butylated hydroxytoluene; nerol; sweet orange oil terpenes and terpenoids; geranyl propionate; gamma-heptalactone; linalyl isobutyrate; ethyl salicylate; 2,6-nonadien-1-ol; dwarf pine-needle oil; ambrette seed oil; methyl anthranilate; dimethyl sulfide; lauryl aldehyde; terpinyl acetate - helps reduce/decrease free radical damage to body cells ; maintain/support cardiovascular system health ; decrease/reduce/relieve diarrhoea ; help maintain/support emotional wellbeing ; decrease/reduce/relieve symptoms of common cold ; decrease/reduce/relieve cough ; decrease/reduce/relieve throat irritation

MUTARS diaphyseal implant silver - Diaphysis prosthesis Australia - English - Department of Health (Therapeutic Goods Administration)

mutars diaphyseal implant silver - diaphysis prosthesis

life healthcare pty ltd - 58084 - diaphysis prosthesis - composed of cocrmo alloy. the surface is sandblasted and provides a silver coating which is applied circumferentially on the extra osseous part of the component. it is to be combined with the mutars connecting part for diaphyseal implant. the two parts are attached to each other by the means of the mutars screws for diaphyseal implant and can be combined with femoral stems & extension pieces depending on the size & position of the resection required. a component of the mutars system intended to bridge diaphyseal bone defects of the femoral bone. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis. the silver coated surface builds a long term prophylaxis against the colonisation of human pathogenic bacteria such as staphylococcus aureus and epidermis, exclusive enterobacteriae and should not be considered as acute treatment.

STRENSIQ asfotase alfa rch 28 mg/0.70 ml solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 28 mg/0.70 ml solution for injection vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.

STRENSIQ asfotase alfa rch 18 mg/0.45 ml solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 18 mg/0.45 ml solution for injection vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.

STRENSIQ asfotase alfa rch 12 mg/0.30 ml solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 12 mg/0.30 ml solution for injection vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.

STRENSIQ asfotase alfa rch 40 mg/1.00 ml solution for injection  vial Australia - English - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 40 mg/1.00 ml solution for injection vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.

STRENSIQ asfotase alfa rch 80 mg/0.80 mL injection solution vial Australia - English - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 80 mg/0.80 ml injection solution vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 100 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium chloride; monobasic sodium phosphate monohydrate; water for injections - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.